Apyx Medical (NASDAQ:APYX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Apyx Medical (NASDAQ:APYX) to a hold rating in a report issued on Saturday.

APYX has been the subject of several other research reports. Citizens Jmp raised Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price for the company in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Apyx Medical in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.00.

Apyx Medical Trading Down 3.3%

Shares of Apyx Medical stock opened at $3.87 on Friday. The company has a quick ratio of 3.95, a current ratio of 4.72 and a debt-to-equity ratio of 4.61. Apyx Medical has a 12-month low of $0.76 and a 12-month high of $4.44. The company has a market capitalization of $148.00 million, a price-to-earnings ratio of -8.60 and a beta of 1.60. The firm’s 50-day moving average price is $3.03 and its two-hundred day moving average price is $2.33.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $12.00 million. Apyx Medical had a negative net margin of 37.11% and a negative return on equity of 158.22%. Apyx Medical has set its FY 2025 guidance at EPS. On average, analysts forecast that Apyx Medical will post -0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apyx Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in APYX. Citadel Advisors LLC acquired a new position in shares of Apyx Medical during the third quarter worth $28,000. Franklin Resources Inc. bought a new position in Apyx Medical during the 3rd quarter worth $59,000. RPg Family Wealth Advisory LLC acquired a new position in Apyx Medical during the 3rd quarter worth about $163,000. Royce & Associates LP grew its position in shares of Apyx Medical by 1.4% in the 3rd quarter. Royce & Associates LP now owns 2,474,399 shares of the company’s stock valued at $5,295,000 after buying an additional 34,696 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Apyx Medical by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after buying an additional 53,175 shares during the last quarter. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.